Sanne de Haas
- Oncology top 2%
- HER2/EGFR in Cancer Research 12
- Cancer Treatment and Pharmacology 8
- Colorectal Cancer Treatments and Studies 7
- Cancer Immunotherapy and Biomarkers 4
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 9
- Breast Cancer Treatment Studies 7
-
- Advanced Breast Cancer Therapies 8
- Renal cell carcinoma treatment 4
- Hepatology top 5%
- Gastroenterology top 5%
- Co-authors
- Stefan SchererPeter CarmelietDiether LambrechtsPaul DelmarEric Van CutsemHeinz‐Josef LenzJoop van GervenAdam F. Cohen
- Journals
- Journal of Clinical Oncology (9 papers)Cancer Research (4 papers)Clinical Cancer Research (3 papers)
- Partner nations
- SwitzerlandUnited StatesGermany
In The Last Decade
Sanne de Haas
34 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 86
- Oncology 1.1k
- Cancer Research 351
- Pulmonary and Respiratory Medicine 683
- Hepatology 139
- Gastroenterology 94
Countries citing papers authored by Sanne de Haas
This map shows the geographic impact of Sanne de Haas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanne de Haas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanne de Haas more than expected).
Fields of papers citing papers by Sanne de Haas
This network shows the impact of papers produced by Sanne de Haas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanne de Haas. The network helps show where Sanne de Haas may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sanne de Haas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2023 | 23 | |
| 4 | 2021 | 3 | |
| 5 | 2021 | 3 | |
| 6 | 2019 | 79 | |
| 7 | 2019 | 34 | |
| 8 | 2018 | 173 | |
| 9 | 2014 | 22 | |
| 10 | 2014 | 35 | |
| 11 | 2014 | 91 | |
| 12 | 2012 | 358 | |
| 13 | Serial Zr-89-bevacizumab PET Imaging in Metastatic Renal Cell Carcinoma Patients treated with Sunitinib, or Bevacizumab Plus Interferon. | 2012 | 0 |
| 14 | 2012 | 138 | |
| 15 | 2012 | 129 | |
| 16 | 2012 | 21 | |
| 17 | Genetic Markers in Relation to Bevacizumab-induced Hypertension | 2011 | 1 |
| 18 | 2006 | 54 | |
| 19 | 2004 | 208 | |
| 20 | 1999 | 8 |
About Sanne de Haas
Sanne de Haas is a scholar working on Cancer Research, Oncology and Otorhinolaryngology, having authored 37 papers that have together received 1.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (12 papers), Cancer Genomics and Diagnostics (9 papers), Advanced Breast Cancer Therapies (8 papers), Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Breast Cancer Treatment Studies (7 papers), Renal cell carcinoma treatment (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (351 citations) and Pulmonary and Respiratory Medicine (683 citations). Sanne de Haas has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Stefan Scherer, Peter Carmeliet, Diether Lambrechts, Paul Delmar, Eric Van Cutsem, Heinz‐Josef Lenz, Joop van Gerven, Adam F. Cohen, Al de Weerd and Gerard van Erp. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, European Journal of Cancer and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.